Drug Trial Radar · NCT02043678
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
806
Actual
Start
Mar 30, 2014
Primary completion
Feb 15, 2018
Study completion Feb 8, 2024
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Janssen Research & Development, LLC
- First posted
- Jan 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs to be treated with an X-ray machine.
Conditions
- Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)Drug
50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of NIST update) body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles
Matching placebo (normal saline)Drug
Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles
AbirateroneDrug
1000 mg once daily, oral, with best supportive care
Prednisone/PrednisoloneDrug
5 mg twice daily, oral, with best supportive care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Symptomatic Skeletal Event Free Survival (SSE-FS)Time frame: From randomization until first onset of on-study symptomatic skeletal event (SSE) or death, up to 47 months
Locations
163 sites in 19 countries. Site status is shown where the registry gives one.
Site not named
Anchorage, Alaska
Site not named
Tucson, Arizona
Site not named
Oceanside, California
Site not named
Denver, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Fort Myers, Florida
Site not named
Atlanta, Georgia
Site not named
Jeffersonville, Indiana
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Rockville, Maryland
Site not named
Towson, Maryland
Site not named
Boston, Massachusetts
Site not named
Burlington, Massachusetts
Site not named
Detroit, Michigan
Site not named
Traverse City, Michigan
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Hackensack, New Jersey
Site not named
Poughkeepsie, New York
Site not named
Syracuse, New York
Site not named
Bala-Cynwyd, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Norfolk, Virginia
Site not named
Seattle, Washington
Site not named
Spokane, Washington
Site not named
Wheeling, West Virginia
Site not named
East Melbourne, Australia
Site not named
Randwick, Australia
Site not named
St Leonards, New South Wales, Australia
Site not named
Sydney, New South Wales, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
East Bentleigh, Victoria, Australia
Site not named
Fitzroy, Victoria, Australia
Site not named
Heidelberg, Victoria, Australia
Site not named
Brussels, Belgium
Site not named
Bruxelles - Brussel, Belgium
Site not named
Edegem, Belgium
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.